Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01740609 · ClinicalTrials.gov registry record · Phase 1

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
80
Enrollment target

NCT01740609: Completed Phase 1 study, sponsored by Pfizer.

NCT01740609 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01740609, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
80 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses PF-06342674.

Interventions

  • DRUG Placebo
  • BIOLOGICAL PF-06342674 Dose A
  • BIOLOGICAL PF-06342674 Dose B
  • BIOLOGICAL PF-06342674 Dose C
  • BIOLOGICAL PF-06342674 Dose D

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2012-11
Est. Completion 2014-06
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT01740609 record still lists

NCT01740609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).

The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.

NCT01740609 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01740609 about?

NCT01740609 is a clinical study titled "A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses PF-06342674.

What is the current status of trial NCT01740609?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2012-11. Estimated completion is 2014-06.

What interventions are being tested in trial NCT01740609?

The interventions under investigation include: Placebo (DRUG), PF-06342674 Dose A (BIOLOGICAL), PF-06342674 Dose B (BIOLOGICAL), PF-06342674 Dose C (BIOLOGICAL), PF-06342674 Dose D (BIOLOGICAL).

Who is sponsoring clinical trial NCT01740609?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT01740609's enrollment target sits among peer trials

80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01740609, the US trial registry maintained by the National Library of Medicine. NCT01740609 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.